Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rodrigues, O.
Right arrow Articles by Saldiva, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodrigues, O.
Right arrow Articles by Saldiva, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology, Vol 27, Issue 5 298-304, Copyright © 1997 by Foundation for Promotion of Cancer Research

ORIGINAL ARTICLE

Prognostic significance of argyrophilic nucleolar organizer region (AgNOR) in resected non-small cell lung cancer (NSCLC)

OR Rodrigues, L Antonangelo, N Yagi, H Minamoto, AF Schmidt Junior, VL Capelozzi, S Goldenberg and PH Saldiva
Department of Surgery, Universidade de Mogi das Cruzes, Sao Paulo, Brazil.

The expression of the nucleolar organizer regions (NORs) was quantified in paraffin sections of tumors and lymph node metastasis, by means of digital image analysis, in 75 patients with resected non-small cell lung cancer (NSCLC). Patients were divided in two groups: early stage (stages I and II) and advanced stage (stages IIIa, IIIb and IV). The prognostic significance of AgNOR expression was tested by Cox regression analysis in models controlled for age, sex, vital status, stage and histological type. Tumors at early stages had a lower expression of AgNOR than those at more advanced diseases. The mean values obtained for NORs in advanced disease were almost the same as those in the primary tumors when compared with the corresponding lymph node metastasis (r = 0.90; p < 0.01; linear regression). The prognostic role of AgNOR was significant only for tumors at stages I and II and not for advanced neoplasms (stages IIIa, IIIb and IV). These results encourage the inclusion of AgNOR quantitation in routine material, especially in early lung cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
M. D. Brundage, D. Davies, and W. J. Mackillop
Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress
Chest, September 1, 2002; 122(3): 1037 - 1057.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
P. E. d. O. Carvalho, L. Antonangelo, F. D. C. Bernardi, L. E. V. Leao, O. R. Rodrigues, and V. L. Capelozzi
Useful Prognostic Panel Markers to Express the Biological Tumor Status in Resected Lung Adenocarcinomas
Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 478 - 486.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Sato, Y. Saijo, B. Uchiyama, N. Kumano, S.-i. Sugawara, S. Fujimura, M. Sato, M. Sagawa, K. Ohkuda, K. Koike, et al.
Prognostic Value of Nucleolar Protein p120 in Patients With Resected Lung Adenocarcinoma
J. Clin. Oncol., September 1, 1999; 17(9): 2721 - 2721.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.